Organ-on-a-Chip Resources

A liver microphysiological system to study the delivery and efficacy of oligonucleotide-based therapeutics

We introduce the PhysioMimix Liver MPS to study the delivery of oligonucleotides into the liver and their uptake by PHHs. The Liver MPS produces functional and stable PHH microtissues, enabling the study of gene knockdown and dosing strategies over 14 days.

Evaluating a human DILI assay kit’s ability to unlock complex mechanisms of toxicity

Here, we demonstrate how the PhysioMimix DILI assay kit: Human 24 and PhysioMimix OOC Single-organ System captures more complex mechanisms of human DILI than traditional preclinical approaches to reduce the risk of unforeseen event detection in the clinic.

Developing a translational biomarker panel for use in pre-clinical advanced in vitro studies of Non-alcoholic steatohepatitis

Download the Application Note to discover a primary human Non-alcoholic steatohepatitis (NASH) microphysiological system (MPS) that more closely models the human liver and NASH disease.

Explore the model’s ability to recapitulate an advanced NASH phenotype (characterized by fibrosis), quantify the expression of biomarkers and assess the efficacy of four anti-NASH compounds that entered human clinical trials.

Connecting the gut and liver

A human-relevant dual-organ microphysiological system connecting the gut and liver for preclinical profiling of oral bioavailability

Discover a new PhysioMimix® microphysiological system (MPS) that connects primary human RepliGut® and liver models to overcome the limitations of preclinical drug ADME profiling. Download the Application Note to explore the MPS’ evaluation of Temocapril and Midazolam, demonstrating its ability to provide more accurate predictions and change the risk calculus for safer and more efficient drug development.

Alveolar and Bronchial Microphysiological Systems for respiratory infection research and therapeutics evaluation

Richardson et al

Learn about respiratory diseases and their impact on global health, as well as the potential of CN Bio’s technology in developing new pulmonary therapeutics.

Human liver microphysiological system for predicting the drug-induced liver toxicity of differing drug modalities

Novac et al

The liver is one of the organs most susceptible to drug toxicity and drug-induced liver injury (DILI). With more than 750 FDA-approved drugs known to have a degree of DILI risk, better preclinical models are required to de-risk new therapeutics earlier in the drug development process.​ We assess whether a Liver MPS model could be used to understand the detailed mechanistic aspects of liver toxicity.

Microphysiological system for studying fatty liver disease and its impact on drug-induced liver injury

Kostrzewski et al

As a result of the increased prevalence of diabetes, obesity, and metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease in developed countries. Using better in vitro models to fast-track therapeutic development but also accurately assess DILI risk in NASH patients ahead of the clinic is critical. Here, we show the potential of an in vitro 3D NASH model to accurately identify any DILI-associated risks.

Improved prediction of oral bioavailability using a gut-liver microphysiological system

Abbas, Kostrzewski & Hughes

Central to the development of new drugs is an understanding of their pharmacokinetic properties, in particular their bioavailability. Here, we demonstrate the potential of a true 2-organ gut-liver MPS to better predict human bioavailability and improve in vitro to in vivo correlation.

Drug metabolism in a gut-liver microphysiological system

Abbas, Kostrzewski & Hughes

Studies investigating the efficacy and safety of candidate drugs use a variety of animal models to translate research from the bench to clinical trials and then to the clinic. Here, we demonstrate the potential of multi-organ MPS models for improved predictions of in vivo drug absorption and hepatic clearance rates.

Predicting human drug permeability with a gut microphysiological system

Bray et al

Preclinical drug absorption studies are a key step when developing when therapeutics as they determine how much of orally-administered drug reaches the systemic circulation. Here, we show how we developed and characterized a gut MPS closely aligned to the human small intestine, using the PhysioMimix® Single-Organ system, and demonstrated its utility to predict drug permeability.